Government-Owned Inventions; Availability for Licensing, 64810-64812 [2012-26095]
Download as PDF
<![CDATA[
64810
Federal Register / Vol. 77, No. 205 / Tuesday, October 23, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
National Institutes of Health
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Senior
Medicare Patrol (SMP) Program
Outcome Measurement
Government-Owned Inventions;
Availability for Licensing
Administration for Community
Living, HHS.
SUMMARY:
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
AGENCY:
ACTION:
Notice.
The Administration for
Community Living (ACL) is announcing
that the proposed collection of
information listed below has been
submitted to the Office of Management
and Budget (OMB) for review and
clearance under the Paperwork
Reduction Act of 1995.
SUMMARY:
Submit written comments on the
collection of information by November
23, 2012.
DATES:
Submit written comments
on the collection of information by fax
202.395.5806 or by email to
OIRA_submission@omb.eop.gov, Attn:
OMB Desk Officer for ACL.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Doris Summey at 202.357.3533 or email:
doris.summey@aoa.hhs.gov.
In
compliance with 44 U.S.C. 3507, ACL
has submitted the following proposed
collection of information to OMB for
review and clearance.
Grantees are required by Congress to
provide information for use in program
monitoring and for Government
Performance and Results Act (GPRA)
purposes. This information collection
reports the number of active volunteers,
issues and inquiries received, other
SMP program outreach activities, and
the number of Medicare dollars
recovered, among other SMP
performance outcomes. This
information is used as the primary
method for monitoring the SMP
Projects.
ACL estimates the burden of this
collection of information as follows:
Respondents: 54 SMP grantees at 23
hours per month (276 hours per year,
per grantee). Total Estimated Burden
Hours: 7,452 hours per year.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Kathy Greenlee,
Administrator and Assistant Secretary for
Aging.
[FR Doc. 2012–26091 Filed 10–22–12; 8:45 am]
BILLING CODE 4154–01–P
VerDate Mar<15>2010
17:22 Oct 22, 2012
Jkt 229001
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Zuma Mutant Mice as a Tool for
Investigating Mammalian
Developmental Defects
Description of Technology: In
vertebrates, mutations in different
ribosomal protein subunits result in a
variety of phenotypes, suggesting
unique and perhaps extra-ribosomal
functions for these proteins. DiamondBlackfan Anemia (DBA) is a ribosomal
protein disease, in which the bone
marrow fails to produce red blood cells.
NHGRI investigators recently
generated a mouse line with a mutation
in small ribosomal protein7 (Rps7),
known to be involved in DBA. This line
named Zuma (made with the use of the
mutagen N-ethyl-N-nitrosourea (ENU))
carries a point mutation in exon 7 of
Rps7, which is predicted to cause a
substitution of a conserved amino acid
(pY177S). The mutation results in the
disruption of ribosomal biogenesis, as
well as in abnormal skeletal,
melanocyte, and central nervous system
development. Thus, the Zuma line can
be used as a model of DBA, as well as
a tool for investigating other defects of
mammalian development.
Potential Commercial Applications:
• Animal model of Diamond-Blackfan
Anemia (DBA).
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
• Research tool to study other
mammalian developmental defects.
Competitive Advantages: Not
available elsewhere.
Development Stage:
• Prototype.
• Pre-clinical.
• In vitro data available.
Inventors: William J. Pavan and Dawn
Watkins Chow (NHGRI).
Publication: Manuscript submitted.
Intellectual Property: HHS Reference
No. E–294–2012/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565;
tongb@mail.nih.gov.
Collaborative Research Opportunity:
The Mouse Embryology Section of the
National Human Genome Research
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Diamond-Blackfan
Anemia therapies. For collaboration
opportunities, please contact Claire T.
Driscoll, Director, NHGRI Technology
Transfer Office, at
cdriscoll@mail.nih.gov or 301–594–
2235.
Magnetic Resonance Arterial Wall
Imaging Methods That Compensate for
Patient Aperiodic Intrinsic Cardiac,
Chest Wall, and Blood Flow-Induced
Motions
Description of Technology: The
technology includes MRI methods,
systems, and software for reliably
imaging vasculature and vascular wall
thickness while compensating for
aperiodic intrinsic motion of a patient
during respiration. To overcome the loss
of the orthogonality due to
uncompensated residual motions and
after a lapse of time equal to the trigger
delay commenced at the cardiac cycle,
the system acquires multiple
consecutive time-resolved images of the
arterial wall. The cine images are
processed offline and a wall thickness
measurement is produced.
The method improves arterial wall
imaging by increasing the success rate of
obtaining good and excellent quality
images and imaging slice-vessel
orthogonality. The method also provides
more precise wall measurements and a
more distinct difference between
healthy subjects and patients.
The methodology and system can be
applied to any commercially available
MRI scanner.
Potential Commercial Applications:
• Early detection of vascular disease,
• Research in the field of vascular
disease,
E:\FR\FM\23OCN1.SGM
23OCN1
Federal Register / Vol. 77, No. 205 / Tuesday, October 23, 2012 / Notices
• Non-invasive assessment of the
efficacy of medication and/or lifestyle
changes in vascular health status in a
particular subject, and
• Assessment of the efficacy of new
medications or new uses of existing
medications to treat vascular disease.
Competitive Advantages: Existing
techniques suffer from image
degradation due to aperiodic intrinsic
cardiac, chest wall motions, or other
bulk motion that often cause image blur
and reduced wall sharpness. These
techniques do not adequately address
the time-dependent angular orientation
of the arteries, whereby mispositioning
of the imaged slice may cause
disappearance of the lumen-wall
interface altogether.
In the new technology time-resolved
arterial wall imaging overcomes the loss
of the orthogonality due to
uncompensated residual motion.
Development Stage:
• Prototype.
• Early-stage.
• Pre-clinical.
• In vivo data available (human).
Inventors: Khaled Z. Abd-Elmoniem
(NIDDK), Ahmed Gharib (NIDDK),
Roderic Pettigrew (NIBIB).
Publications:
mstockstill on DSK4VPTVN1PROD with NOTICES
1. Plein S, et al. Three-dimensional
coronary MR angiography performed with
subject-specific cardiac acquisition windows
and motion-adapted respiratory gating. AJR
Am J Roentgenol. 2003 Feb;180(2):505–12.
[PMID 12540462]
2. Hoffmann MH, et al. Automatic
determination of minimal cardiac motion
phases for computed tomography imaging:
Initial experience. Eur Radiol. 2006
Feb;16(2):365–73. [PMID 16021450]
3. Ustun A, et al. Automated identification
of minimal myocardial motion for improved
image quality on MR angiography at 3 T. AJR
Am J Roentgenol. 2007 Mar;188(3):W283–90.
[PMID 17312038]
4. Roes SD, et al. Correction for heart rate
variability during 3D whole heart MR
coronary angiography. J Magn Reson Imaging.
2008 May;27(5):1046–53. [PMID 18425831]
5. Abd-Elmoniem KZ, et al. Phase-sensitive
black-blood coronary vessel wall imaging.
Magn Reson Med. 2010 Apr;63(4):1021–30.
[PMID 20373403]
6. Spuentrup E, et al. The impact of
navigator timing parameters and navigator
spatial resolution on 3D coronary magnetic
resonance angiography. J Magn Reson
Imaging. 2001 Sep;14(3):311–8. [PMID
11536409]
Intellectual Property: HHS Reference
No. E–185–2012/0—U.S. Provisional
Application No. 61/692,191 filed 22
Aug 2012.
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The Biomedical and Metabolic Imaging
VerDate Mar<15>2010
17:22 Oct 22, 2012
Jkt 229001
Branch, NIDDK, NIH, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize time-resolved arterial
wall imaging. For collaboration
opportunities, please contact Khaled Z.
Abd-Elmoniem at
abdelmoniemkz@mail.nih.gov.
Topical Antibiotic With Immune
Stimulating Oligodeoxynucleotide
Molecules To Speed Wound Healing
Description of Technology: The
present technology provides a mean of
improving the activity of topical
antibiotics. Currently available topical
antibiotic formulations effectively
eliminate bacteria at a wound site. But
in eliminating bacteria in the wound,
such antibiotics also eliminate the
molecular signals present in bacterial
DNA that stimulate to immune system’s
wound healing processes. Without these
signals the rate of wound healing is
diminished. It would be desirable for
topical antibiotics to remove infectious
bacteria but also provide the immune
stimulating signals needed to promote
and accelerate healing. The present
formulation accomplishes these goals by
supplementing the antibiotic
formulation with immunostimulatory
oligodeoxynucleotides (ODN). These
ODN express the CpG motifs present in
bacterial DNA and safely mimic the
immune stimulation induced by
bacterial DNA. The formulation may be
applied directly to a wide variety of
wounds to skin (such as traumatic,
burn, or surgical wound), or the eyes
(such as corneal abrasions) to effectively
eliminate infection and stimulate rapid
healing of the wound.
Potential Commercial Applications:
Topical antibiotic.
Competitive Advantages: Eliminates
wound site bacteria while retaining
immune stimulating properties that
promote faster wound healing.
Development Stage:
• Early-stage.
• In vivo data available (animal).
Inventors: Dennis Klinman, Hiroyasu
Ito, Noriho Iida (all of NCI).
Publications:
1. Ito H, et al. Antibiotics delay wound
healing: An effect reversed by coadministering TLR7 and 9 ligands. Current
Angiogenesis. 2012 Apr;1(1):46–51.
2. Sato T, et al. Accelerated wound healing
mediated by activation of Toll-like receptor
9. Wound Repair Regen. 2010 Nov–
Dec;18(6):586–93. [PMID 20946144]
3. Yamamoto M, et al. The acceleration of
wound healing in primates by the local
administration of immunostimulatory CpG
oligonucleotides. Biomaterials. 2011
Jun;32(18):4238–42. [PMID 21421264]
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
64811
Intellectual Property: HHS Reference
No. E–294–2011/0—U.S. Provisional
Application No. 61/639,688 filed 27 Apr
2012.
Related Technology: HHS Reference
No. E–242–2007/0—U.S. Patent
Application No. 12/205,756 filed 05 Sep
2008.
Licensing Contact: Edward (Tedd)
Fenn; 301–435–5031;
fenned@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize adding
immunostimulatory CpG
oligonucleotides to a topical antibiotic
formulation to accelerate wound
healing. For collaboration opportunities,
please contact John Hewes, Ph.D. at
hewesj@mail.nih.gov.
Antimalarial Inhibitors That Target the
Plasmodial Surface Anion Channel
(PSAC) Protein and Development of the
PSAC Protein as Vaccine Targets
Description of Technology: There are
two related technologies, the first being
small molecule inhibitors of the
malarial plasmodial surface anion
channel (PSAC) and the second being
the PSAC protein itself as a vaccine
candidate. The PSAC protein is
produced by the malaria parasite within
host erythrocytes and is crucial for
mediating nutrient uptake. In vitro data
show that the PSAC inhibitors are able
to inhibit growth of malaria parasites,
have high specificity, and low toxicity.
Portions of the PSAC protein are found
on the outer surface of infected host
erythrocytes and the protein was
recently shown to be encoded by the
clag3 gene. This discovery opens the
possibility of developing the PSAC
protein as a potential vaccine candidate
against malaria.
Potential Commercial Applications:
• Antimalarial Drugs.
• Malaria Vaccine.
Competitive Advantages:
• Novel target against malaria.
• Small molecule inhibitors of PSAC
inhibit malarial parasite growth, have
low toxicity, and high specificity.
• PSAC protein is exposed on the
surface of the infected host erythrocytes,
making it an attractive vaccine
candidate.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
Inventor: Sanjay Desai (NIAID).
Publications:
1. Pillai AD, et al. Solute restriction reveals
an essential role for clag3-associated
E:\FR\FM\23OCN1.SGM
23OCN1
64812
Federal Register / Vol. 77, No. 205 / Tuesday, October 23, 2012 / Notices
channels in malaria parasite nutrient
acquisition. Mol Pharmacol. 2012 Sep 4;
Epub ahead of print. [PMID 22949525]
2. Desai SA. Ion and nutrient uptake by
malaria parasite-infected erythrocytes. Cell
Microbiol. 2012 Jul;14(7):1003–9. [PMID
22432505]
3. Nguitragool W, et al. Malaria parasite
clag3 genes determine channel-mediated
nutrient uptake by infected red blood cells.
Cell. 2011 May 27;145(5):665–77. [PMID
21620134]
4. Pillai AD, et al. A cell-based highthroughput screen validates the plasmodial
surface anion channel as an antimalarial
target. Mol Pharmacol. 2010 May;77(5):724–
33. [PMID 20101003]
mstockstill on DSK4VPTVN1PROD with NOTICES
Intellectual Property: HHS Reference
No. E–145–2011/0—International PCT
Patent Application No. PCT/US12/
33072 filed 11 Apr 2012.
Related Technology: HHS Reference
No. E–202–2008/0—Patent family filed
in the U.S., Europe, Brazil, India, and
China.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Antimalarial Inhibitors
that Target the Plasmodial Surface
Anion Channel (PSAC) Protein. For
collaboration opportunities, please
contact Dana Hsu at
dhsu@niaid.nih.gov. or 301–451–3521.
Fluorescent Magnesium Indicators
Description of Technology: A noninvasive approach in which Magnesium
(Mg2+) ion levels can be measured in
real-time. Mg2+ is essential to many
physio-chemical processes and plays a
central role in the biochemistry of all
cells. Many epidemiological studies
have established close association
between plasma magnesium levels and
various diseases including
cardiovascular disease and
hypertension. However, methods and
tools to selectively measure cellular
magnesium levels in the body with
accuracy and reliability are still lacking
in the market today. The present
invention provides novel fluorescent
indicators (carboxy-quinolizones) that
are selective for Mg2+ and can be easily
detected using fluorescence
spectroscopy.
Current approaches used to measure
intracellular magnesium in the body
generally involve magnetic resonance
spectroscopy, which is extremely
expensive and subject to very poor
accuracy. Unlike these other methods,
the fluorescence indicators of this
VerDate Mar<15>2010
17:22 Oct 22, 2012
Jkt 229001
invention provide a more accurate way
to measure intracellular and
extracellular Mg2+ levels in a wide
variety of biological settings and have
potential to be developed into
diagnostic reagents.
Potential Commercial Applications:
• Tool for measuring intracellular and
extracellular magnesium levels.
• Diagnostic reagent for measuring
magnesium levels in a human or animal.
Competitive Advantages:
• Increased accuracy compared to
what is available on the market.
• Detection is noninvasive.
• Ease of use.
Development Stage:
• Early-stage.
• In vitro data available.
Inventors: Robert E. London, Pieter
Otten, Louis A. Levy (all of NIEHS).
Publications:
1. Raju B, et al. A fluorescent indicator for
measuring cytosolic free magnesium. Am J
Physiol. 1989 Mar;256(3 Pt 1):C540–8. [PMID
2923192]
2. Otten PA, et al. 4-Oxo-4H-quinolizine-3carboxylic acids as Mg2+-selective,
fluorescent indicators. Bioconjugate Chem.
2001 Mar–Apr;12(2):203–12. [PMID
11312681]
Intellectual Property: HHS Reference
No. E–067–2000/0 — U.S. Patent No.
6,706,528 issued 16 Mar 2004.
Licensing Contact: Suryanarayana
Vepa, Ph.D., J.D.; 301–435–5020;
vepas@mail.nih.gov.
Collaborative Research Opportunity:
The NIEHS is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the fluorescent
magnesium indicators. For collaboration
opportunities, please contact Elizabeth
M. Denholm, Ph.D. at
denholme@niehs.nih.gov.
Dated October 18, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–26095 Filed 10–22–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
PO 00000
Frm 00019
Fmt 4703
Sfmt 9990
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Peer Review of SCORE Grant
Applications.
Date: November 15–16, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: DoubleTree by Hilton Bethesda,
8120 Wisconsin Avenue, Bethesda, MD
20814.
Contact Person: Saraswathy Seetharam,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, 45 Center Drive, Room 3An12C,
Bethesda, MD 20892, 301–594–2763,
seetharams@nigms.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; NIGMS Predoctoral T32 Review SEP.
Date: November 16, 2012.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3An18K, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Brian R. Pike, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3An18, Bethesda,
MD 20892, 301–594–3907,
pikebr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: October 17, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–26012 Filed 10–22–12; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 77, Number 205 (Tuesday, October 23, 2012)]
[Notices]
[Pages 64810-64812]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-26095]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Zuma Mutant Mice as a Tool for Investigating Mammalian Developmental
Defects
Description of Technology: In vertebrates, mutations in different
ribosomal protein subunits result in a variety of phenotypes,
suggesting unique and perhaps extra-ribosomal functions for these
proteins. Diamond-Blackfan Anemia (DBA) is a ribosomal protein disease,
in which the bone marrow fails to produce red blood cells.
NHGRI investigators recently generated a mouse line with a mutation
in small ribosomal protein7 (Rps7), known to be involved in DBA. This
line named Zuma (made with the use of the mutagen N-ethyl-N-nitrosourea
(ENU)) carries a point mutation in exon 7 of Rps7, which is predicted
to cause a substitution of a conserved amino acid (pY177S). The
mutation results in the disruption of ribosomal biogenesis, as well as
in abnormal skeletal, melanocyte, and central nervous system
development. Thus, the Zuma line can be used as a model of DBA, as well
as a tool for investigating other defects of mammalian development.
Potential Commercial Applications:
Animal model of Diamond-Blackfan Anemia (DBA).
Research tool to study other mammalian developmental
defects.
Competitive Advantages: Not available elsewhere.
Development Stage:
Prototype.
Pre-clinical.
In vitro data available.
Inventors: William J. Pavan and Dawn Watkins Chow (NHGRI).
Publication: Manuscript submitted.
Intellectual Property: HHS Reference No. E-294-2012/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
tongb@mail.nih.gov.
Collaborative Research Opportunity: The Mouse Embryology Section of
the National Human Genome Research Institute is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize Diamond-
Blackfan Anemia therapies. For collaboration opportunities, please
contact Claire T. Driscoll, Director, NHGRI Technology Transfer Office,
at cdriscoll@mail.nih.gov or 301-594-2235.
Magnetic Resonance Arterial Wall Imaging Methods That Compensate for
Patient Aperiodic Intrinsic Cardiac, Chest Wall, and Blood Flow-Induced
Motions
Description of Technology: The technology includes MRI methods,
systems, and software for reliably imaging vasculature and vascular
wall thickness while compensating for aperiodic intrinsic motion of a
patient during respiration. To overcome the loss of the orthogonality
due to uncompensated residual motions and after a lapse of time equal
to the trigger delay commenced at the cardiac cycle, the system
acquires multiple consecutive time-resolved images of the arterial
wall. The cine images are processed offline and a wall thickness
measurement is produced.
The method improves arterial wall imaging by increasing the success
rate of obtaining good and excellent quality images and imaging slice-
vessel orthogonality. The method also provides more precise wall
measurements and a more distinct difference between healthy subjects
and patients.
The methodology and system can be applied to any commercially
available MRI scanner.
Potential Commercial Applications:
Early detection of vascular disease,
Research in the field of vascular disease,
[[Page 64811]]
Non-invasive assessment of the efficacy of medication and/
or lifestyle changes in vascular health status in a particular subject,
and
Assessment of the efficacy of new medications or new uses
of existing medications to treat vascular disease.
Competitive Advantages: Existing techniques suffer from image
degradation due to aperiodic intrinsic cardiac, chest wall motions, or
other bulk motion that often cause image blur and reduced wall
sharpness. These techniques do not adequately address the time-
dependent angular orientation of the arteries, whereby mispositioning
of the imaged slice may cause disappearance of the lumen-wall interface
altogether.
In the new technology time-resolved arterial wall imaging overcomes
the loss of the orthogonality due to uncompensated residual motion.
Development Stage:
Prototype.
Early-stage.
Pre-clinical.
In vivo data available (human).
Inventors: Khaled Z. Abd-Elmoniem (NIDDK), Ahmed Gharib (NIDDK),
Roderic Pettigrew (NIBIB).
Publications:
1. Plein S, et al. Three-dimensional coronary MR angiography
performed with subject-specific cardiac acquisition windows and
motion-adapted respiratory gating. AJR Am J Roentgenol. 2003
Feb;180(2):505-12. [PMID 12540462]
2. Hoffmann MH, et al. Automatic determination of minimal
cardiac motion phases for computed tomography imaging: Initial
experience. Eur Radiol. 2006 Feb;16(2):365-73. [PMID 16021450]
3. Ustun A, et al. Automated identification of minimal
myocardial motion for improved image quality on MR angiography at 3
T. AJR Am J Roentgenol. 2007 Mar;188(3):W283-90. [PMID 17312038]
4. Roes SD, et al. Correction for heart rate variability during
3D whole heart MR coronary angiography. J Magn Reson Imaging. 2008
May;27(5):1046-53. [PMID 18425831]
5. Abd-Elmoniem KZ, et al. Phase-sensitive black-blood coronary
vessel wall imaging. Magn Reson Med. 2010 Apr;63(4):1021-30. [PMID
20373403]
6. Spuentrup E, et al. The impact of navigator timing parameters
and navigator spatial resolution on 3D coronary magnetic resonance
angiography. J Magn Reson Imaging. 2001 Sep;14(3):311-8. [PMID
11536409]
Intellectual Property: HHS Reference No. E-185-2012/0--U.S.
Provisional Application No. 61/692,191 filed 22 Aug 2012.
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The Biomedical and Metabolic
Imaging Branch, NIDDK, NIH, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize time-resolved arterial wall
imaging. For collaboration opportunities, please contact Khaled Z. Abd-
Elmoniem at abdelmoniemkz@mail.nih.gov.
Topical Antibiotic With Immune Stimulating Oligodeoxynucleotide
Molecules To Speed Wound Healing
Description of Technology: The present technology provides a mean
of improving the activity of topical antibiotics. Currently available
topical antibiotic formulations effectively eliminate bacteria at a
wound site. But in eliminating bacteria in the wound, such antibiotics
also eliminate the molecular signals present in bacterial DNA that
stimulate to immune system's wound healing processes. Without these
signals the rate of wound healing is diminished. It would be desirable
for topical antibiotics to remove infectious bacteria but also provide
the immune stimulating signals needed to promote and accelerate
healing. The present formulation accomplishes these goals by
supplementing the antibiotic formulation with immunostimulatory
oligodeoxynucleotides (ODN). These ODN express the CpG motifs present
in bacterial DNA and safely mimic the immune stimulation induced by
bacterial DNA. The formulation may be applied directly to a wide
variety of wounds to skin (such as traumatic, burn, or surgical wound),
or the eyes (such as corneal abrasions) to effectively eliminate
infection and stimulate rapid healing of the wound.
Potential Commercial Applications: Topical antibiotic.
Competitive Advantages: Eliminates wound site bacteria while
retaining immune stimulating properties that promote faster wound
healing.
Development Stage:
Early-stage.
In vivo data available (animal).
Inventors: Dennis Klinman, Hiroyasu Ito, Noriho Iida (all of NCI).
Publications:
1. Ito H, et al. Antibiotics delay wound healing: An effect
reversed by co-administering TLR7 and 9 ligands. Current
Angiogenesis. 2012 Apr;1(1):46-51.
2. Sato T, et al. Accelerated wound healing mediated by
activation of Toll-like receptor 9. Wound Repair Regen. 2010 Nov-
Dec;18(6):586-93. [PMID 20946144]
3. Yamamoto M, et al. The acceleration of wound healing in
primates by the local administration of immunostimulatory CpG
oligonucleotides. Biomaterials. 2011 Jun;32(18):4238-42. [PMID
21421264]
Intellectual Property: HHS Reference No. E-294-2011/0--U.S.
Provisional Application No. 61/639,688 filed 27 Apr 2012.
Related Technology: HHS Reference No. E-242-2007/0--U.S. Patent
Application No. 12/205,756 filed 05 Sep 2008.
Licensing Contact: Edward (Tedd) Fenn; 301-435-5031;
fenned@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize adding immunostimulatory CpG oligonucleotides to a
topical antibiotic formulation to accelerate wound healing. For
collaboration opportunities, please contact John Hewes, Ph.D. at
hewesj@mail.nih.gov.
Antimalarial Inhibitors That Target the Plasmodial Surface Anion
Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine
Targets
Description of Technology: There are two related technologies, the
first being small molecule inhibitors of the malarial plasmodial
surface anion channel (PSAC) and the second being the PSAC protein
itself as a vaccine candidate. The PSAC protein is produced by the
malaria parasite within host erythrocytes and is crucial for mediating
nutrient uptake. In vitro data show that the PSAC inhibitors are able
to inhibit growth of malaria parasites, have high specificity, and low
toxicity. Portions of the PSAC protein are found on the outer surface
of infected host erythrocytes and the protein was recently shown to be
encoded by the clag3 gene. This discovery opens the possibility of
developing the PSAC protein as a potential vaccine candidate against
malaria.
Potential Commercial Applications:
Antimalarial Drugs.
Malaria Vaccine.
Competitive Advantages:
Novel target against malaria.
Small molecule inhibitors of PSAC inhibit malarial
parasite growth, have low toxicity, and high specificity.
PSAC protein is exposed on the surface of the infected
host erythrocytes, making it an attractive vaccine candidate.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Inventor: Sanjay Desai (NIAID).
Publications:
1. Pillai AD, et al. Solute restriction reveals an essential
role for clag3-associated
[[Page 64812]]
channels in malaria parasite nutrient acquisition. Mol Pharmacol.
2012 Sep 4; Epub ahead of print. [PMID 22949525]
2. Desai SA. Ion and nutrient uptake by malaria parasite-
infected erythrocytes. Cell Microbiol. 2012 Jul;14(7):1003-9. [PMID
22432505]
3. Nguitragool W, et al. Malaria parasite clag3 genes determine
channel-mediated nutrient uptake by infected red blood cells. Cell.
2011 May 27;145(5):665-77. [PMID 21620134]
4. Pillai AD, et al. A cell-based high-throughput screen
validates the plasmodial surface anion channel as an antimalarial
target. Mol Pharmacol. 2010 May;77(5):724-33. [PMID 20101003]
Intellectual Property: HHS Reference No. E-145-2011/0--
International PCT Patent Application No. PCT/US12/33072 filed 11 Apr
2012.
Related Technology: HHS Reference No. E-202-2008/0--Patent family
filed in the U.S., Europe, Brazil, India, and China.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
changke@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize Antimalarial Inhibitors that Target
the Plasmodial Surface Anion Channel (PSAC) Protein. For collaboration
opportunities, please contact Dana Hsu at dhsu@niaid.nih.gov. or 301-
451-3521.
Fluorescent Magnesium Indicators
Description of Technology: A non-invasive approach in which
Magnesium (Mg2+) ion levels can be measured in real-time. Mg2+ is
essential to many physio-chemical processes and plays a central role in
the biochemistry of all cells. Many epidemiological studies have
established close association between plasma magnesium levels and
various diseases including cardiovascular disease and hypertension.
However, methods and tools to selectively measure cellular magnesium
levels in the body with accuracy and reliability are still lacking in
the market today. The present invention provides novel fluorescent
indicators (carboxy-quinolizones) that are selective for Mg2+ and can
be easily detected using fluorescence spectroscopy.
Current approaches used to measure intracellular magnesium in the
body generally involve magnetic resonance spectroscopy, which is
extremely expensive and subject to very poor accuracy. Unlike these
other methods, the fluorescence indicators of this invention provide a
more accurate way to measure intracellular and extracellular Mg2+
levels in a wide variety of biological settings and have potential to
be developed into diagnostic reagents.
Potential Commercial Applications:
Tool for measuring intracellular and extracellular
magnesium levels.
Diagnostic reagent for measuring magnesium levels in a
human or animal.
Competitive Advantages:
Increased accuracy compared to what is available on the
market.
Detection is noninvasive.
Ease of use.
Development Stage:
Early-stage.
In vitro data available.
Inventors: Robert E. London, Pieter Otten, Louis A. Levy (all of
NIEHS).
Publications:
1. Raju B, et al. A fluorescent indicator for measuring
cytosolic free magnesium. Am J Physiol. 1989 Mar;256(3 Pt 1):C540-8.
[PMID 2923192]
2. Otten PA, et al. 4-Oxo-4H-quinolizine-3-carboxylic acids as
Mg2+-selective, fluorescent indicators. Bioconjugate Chem. 2001 Mar-
Apr;12(2):203-12. [PMID 11312681]
Intellectual Property: HHS Reference No. E-067-2000/0 -- U.S.
Patent No. 6,706,528 issued 16 Mar 2004.
Licensing Contact: Suryanarayana Vepa, Ph.D., J.D.; 301-435-5020;
vepas@mail.nih.gov.
Collaborative Research Opportunity: The NIEHS is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize the fluorescent
magnesium indicators. For collaboration opportunities, please contact
Elizabeth M. Denholm, Ph.D. at denholme@niehs.nih.gov.
Dated October 18, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-26095 Filed 10-22-12; 8:45 am]
BILLING CODE 4140-01-P
